SCHEMBL29465769

SCHEMBL29465769

O=Cc1ncc(Cl)nc1Cl

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33
KCNJ1 P48048 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376744 1.00 ALDH1A1 (0.33) ALDH1A1KCNJ1
SCHEMBL14775276 0.82
SCHEMBL26920416 0.80 SGK1 (0.33) ALDH1A1
SCHEMBL29844672 0.78 KCNJ1 (0.46) ALDH1A1KCNJ1
SCHEMBL22678487 0.78 KCNJ1 (0.46) ALDH1A1KCNJ1
SCHEMBL29956623 0.78 CDK2 (0.35) ALDH1A1
SCHEMBL30901440 0.77 PDCD1 (0.45)
SCHEMBL21290658 0.77 PDCD1 (0.45)
SCHEMBL23214420 0.74 ALDH1A1 (0.39) ALDH1A1KCNJ1
SCHEMBL29955836 0.74 GRM5 (0.36) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118772157-A Synthesis method of 6-chloro-1H-pyrazolo [3,4-B ] pyrazine 浙江江北南海药业有限公司 2024-10-15 CN claimed
WO-2025092905-A1 PARP INHIBITORS AND USES THEREOF SUZHOU EOC MEDICAL RESEARCH CO., LTD. (CN) 2025-05-08 WO disclosed
WO-2025091346-A1 PARP INHIBITORS AND USES THEREOF SUZHOU EOC MEDICAL RESEARCH CO., LTD. (CN) 2025-05-08 WO disclosed
CN-118772157-A Synthesis method of 6-chloro-1H-pyrazolo [3,4-B ] pyrazine 浙江江北南海药业有限公司 2024-10-15 CN disclosed
CN-118772157-A Synthesis method of 6-chloro-1H-pyrazolo [3,4-B ] pyrazine 浙江江北南海药业有限公司 2024-10-15 CN disclosed
CN-118084940-A PD-1/PD-L1 inhibitors 吉利德科学公司 2024-05-28 CN disclosed
CN-117263942-A SHP2 phosphatase inhibitors and methods of use thereof 传达治疗有限公司 2023-12-22 CN disclosed
CN-116731038-A Nitrogen-containing heterocyclic compound, and preparation method and application thereof 苏州亚盛药业有限公司 2023-09-12 CN disclosed
CN-112166110-B SHP2 phosphatase inhibitors and methods of use thereof 传达治疗有限公司 2023-08-11 CN disclosed
EP-3515916-B1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2023-06-07 EP disclosed
US-11529347-B2 SHP2 phosphatase inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2022-12-20 US disclosed
EP-3983413-A1 SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2022-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11529347-B2 SHP2 phosphatase inhibitors and methods of use thereof PTPN21, PTPN22, PTPN5 ALDH1A1 4124/4885KCNJ1 4001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.